Bausch Health Companies Inc. Stock
$5.26
7.32%
today
NYSE,
Apr 04, 09:17 pm CET
Bausch Health Companies Inc. Stock price
$5.67
-1.50
20.92%
1M
-2.60
31.44%
6M
-2.39
29.65%
YTD
-4.37
43.53%
1Y
-17.96
76.01%
3Y
-7.64
57.40%
5Y
-192.78
97.14%
10Y
NYSE,
Closing price Thu, Apr 03 2025
-0.44
7.20%
Powered by
ISIN
CA0717341071
Symbol
BHC
Index
Sector
Industry
Key metrics
| Market capitalization | $2.09b |
| Enterprise Value | $23.68b |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 19.26 |
| EV/Sales (TTM) EV/Sales | 2.46 |
| P/S ratio (TTM) P/S ratio | 0.22 |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue growth (TTM) Revenue growth | 9.91% |
| Revenue (TTM) Revenue | $9.63b |
Show more
Is Bausch Health Companies Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
Bausch Health Companies Inc. Stock Analysis
Unlock Scores for Free
Analyst Opinions
6 Analysts have issued a Bausch Health Companies Inc. forecast:
Analyst Opinions
6 Analysts have issued a Bausch Health Companies Inc. forecast:
Hold
83%
Sell
17%
Financial data from Bausch Health Companies Inc.
| Dec '24 |
+/-
%
|
||
| Revenue | 9,625 9,625 |
10%
10%
|
|
| Gross Profit | 5,766 5,766 |
13%
13%
|
|
| EBITDA | 3,121 3,121 |
9%
9%
|
EBIT (Operating Income) EBIT | 1,854 1,854 |
15%
15%
|
| Net Profit | -46 -46 |
92%
92%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Bausch Health Companies Inc. directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bausch Health Companies Inc. Stock News
Neutral
Accesswire
●
2 days ago
Bausch Health's gastroenterology business, Salix Pharmaceuticals, recognizes the complexities of irritable bowel syndrome (IBS) and seeks to make a difference in how the condition is perceived, diagnosed and treated. LAVAL, QC / ACCESS Newswire / April 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today anno...
Negative
Reuters
●
8 days ago
Bausch + Lomb said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could not immediately be known.
Negative
Market Watch
●
8 days ago
The Canadian eyecare company said Thursday that it has made a voluntary recall of its intraocular lenses on its enVista platform.
Company Profile
Manufactures and markets pharmaceutical products
| Head office | Canada |
| CEO | Thomas Appio |
| Employees | 20,700 |
| Founded | 1994 |
| Website | www.bauschhealth.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
